Aspirin: Past, present and future

Clinical Medicine

Volumn 1, Issue 2, 2001, Pages 132-137

  Elwood, Peter C ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE;

ARTICLE; CANCER; CLINICAL TRIAL; DEMENTIA; DRUG INDICATION; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HISTORY OF MEDICINE; HUMAN; NEUTROPENIA; PROPHYLAXIS; RISK BENEFIT ANALYSIS; THROMBOCYTE; THROMBOSIS;

EID: 0035043453     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.1-2-132     Document Type: Article

References (40)

1. Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans 1763;53:195-200.
2. Kroneberg HG. Historical remarks on acetyl salicylic acid. In: Lee M (ed). 1982 Seoul International Aspirin Symposium Proceedings. Seoul: Dong Bu I-chon Dong, 1982:5-17.
3. Wilthauer J, Wohlgemut J. Uber aspirine (acetylsalicylsaure). Ther Mh (Halbmh) 1899;13:276.
4. Donné A. De l'origine des globules du sang, de leur mode de formation et de leur fin. Compt Acad Sci 1842;14:366-8.
5. Osler W. An account of certain organisms occurring in the liquor sanguinis. Proc R Soc Lond 1874;5:692-734.
6. Haerem JW. Platelet aggregates and mural microthrombin in the early stages of acute phase of coronary disease. Thromb Res 1974;5:243.
7. Davies MJ, Thomas AC. Thrombosis and acute coronary-artery lesions in sudden cardiac ischaemic death. N Eng J Med 1984;10:1137-40.
8. Morris CDW. Acetylsalicylic acid and platelet stickiness. Lancet 1967;I:279-80.
9. O'Brien JR. Effects of salicylates on human platelets. Lancet 1968;I:779-83.
10. Stuart RK. Platelet function studies in human beings receiving 300 mg of aspirin per day. J Lab Clin Med 1970;75:463-71.
11. Rocca B, Fitzgerald GA. Erythrocytes modulate platelet function. Should we rethink the way we give aspirin? Circulation 1997;95:11-13.
12. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, et al. A randomised, controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1974;I:436-40.
13. Antiplatelet Trialists' Collaboration. Collaborative overview of random trials of anti-platelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged anti-platelet therapy in various categories of patients. Br Med J 1994;308:81-106.
14. Glynn RJ, Buring JE, Manson JE, LaMotte F, et al. Adherence to aspirin in the prevention of myocardial infarction: The Physicians' Health Study. Arch Intern Med 1994;154:2649-57.
15. Garcia-Dorado D, Therous P, Tornos P, Sambola A, et al. Previous aspirin use may attenuate the severity of the manifestation of acute ischaemic syndromes. Circulation 1995;92:1743-8.
16. Ginj J van. Low doses of aspirin in stroke prevention. Lancet 1999;353:2172-3.
17. Chinese Acute Stroke Collaborative Group (CAST). Chinese Acute Stroke Collaborative Group: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-7.
18. International Stroke Trial Collaborative Group. A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
19. Kmietowicz Z. Aspirin benefits patients with stroke - but only just. Br Med J 1997;314:1646.
20. Hellemons BSP, Langenberg M, Lodder J, Vermeer F, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. Br Med J 1999;319:958-64.
21. Anon. Prevention of pulmonary embolism and deep vein thrombosis with low-dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;355:1295-302.
22. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the on-going Physicians' Health Study. N Engl J Med 1989;321:129-35.
23. Peto R, Gray R, Collins R, Wheatley K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313-6.
24. Medical Research Council. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351:233-41.
25. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-5.
26. The health of the nation: assessing the options: CHD/Stroke. Target effectiveness and cost-effectiveness of interventions to reduce coronary heart disease and stroke mortality. London: Department of Health, 1995.
27. Tofler GH, Brezinski DA, Schafer AI, Czeisler CA, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infacrtion and sudden cardiac death. N Engl J Med 1987;316:1514-8.
28. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomised trial of physicians. Circulation 1990;82:897-902.
29. Second International Study of Infarct Survival Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: IS1S-2. Lancet 1988;ii:349-60.
30. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991;12:428-33.
31. Dabaghi SF, Kamat SG, Payne J, Marks GF, et al. Effects of low-dose aspirin on in-vitro platelet aggregation in the early minutes after injestion in normal subjects. Am J Cardiol 1994;74:720-3.
32. Stein B, Fuster V. Role of platelet inhibitor therapy in myocardial infarction. Cardiovasc Drugs Ther 1989;3:797-85.
33. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Safety 1998;19:89-98.
34. CAPRIE Steering Committee. Randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events. (CAPRIE). Lancet 1996;348:1329-36.
35. Collins R, MacMahon S, Flather M, Baigent C, et al. Clinical effects of anbticoagulant therapy in suspected myocardial infarction: systematic overview of randomised trials. Br Med J 1996;313:652-9.
36. Choussat R, Montalescot G. Blocking platelets more: are we skating on thin ice? Heart 1998;79:5-6.
37. Belsey J. Lipid-lowering in coronary heart disease. Gavel: Evidence based medicine in practice. 1998;1:2-8.
38. Richards M, Meade TW, Peart S, Brennan PJ, Mann AH. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? J Neurol Psychiat 1997;62:269-72.
39. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
40. Morgan G. Beneficial effects of NSAIDs in the gastrointestinal tract. Eur J Gastroenterol Hepatol 1999;11:393-400.